(Adds details from Justice Department settlement)
BOSTON, Sept 22 (Reuters) - Aegerion Pharmaceuticals Inc will plead guilty to two misdemeanors and pay $40 million to resolve investigations into its marketing and sales of a cholesterol drug, U.S. prosecutors and regulators announced on Friday.
The settlements will resolve long-running investigations into Aegerion, a subsidiary of Canada's Novelion Therapeutics Inc, by the U.S. Justice Department and the U.S. Securities and Exchange Commission related to its drug Juxtapid.
The settlements finalized preliminary agreements Aegerion first disclosed in May 2016. The Cambridge, Massachusetts-based company in November merged with QLT Inc and became a subsidiary of the newly named Novelion Therapeutics. (Reporting by Nate Raymond; Editing by Jonathan Oatis)